Literature DB >> 20821015

Functional effects of β₁-adrenoceptor polymorphisms on the hemodynamic response to dobutamine with and without β-blocker administration.

Michael Kindermann1, Ute Seeland, Patrick Ruhnke, Michael Böhm, Christoph Maack.   

Abstract

BACKGROUND: The relevance of the Arg389Gly- and Ser49Gly-β₁-adrenoceptor (AR) polymorphisms for cardiovascular function and pharmacotherapy is controversial.
METHODS: Out of 38 healthy male volunteers who were screened for both types of the β₁-AR polymorphism 23 subjects underwent dobutamine stress echocardiography at baseline, after administration of metoprolol succinate (n = 18, 190 mg/day) and 44 h after abrupt termination of the β-blocker (n = 17). Heart rate (HR), systolic blood pressure (SAP), HR-corrected left ventricular circumferential fiber shortening (VCF(C)), cardiac output (CO), systemic vascular resistance (SVR) and left ventricular end-systolic meridional wall stress (EsMWS) were measured. β₁-AR gene polymorphisms were analyzed by TaqMan-PCR.
RESULTS: Genotype frequency distributions and allele frequencies of the Gly389Arg and Ser49Gly polymorphisms of the β₁-AR were similar to published data. Although body surface area was similar for Arg/Arg subjects and Gly carriers the latter group revealed smaller left ventricular end-diastolic (-0.4 cm, p = 0.04) and end-systolic LV dimensions (-0.4 cm, p = 0.01). During dobutamine stimulation before, during and after termination of metoprolol coadministration no significant effect of the Arg389Gly-β₁-AR polymorphism on HR, SAP, CO and VCF(c) was detected. In contrast, SVR (p = 0.01) and EsMWS (p = 0.04) were significantly higher in Arg/Arg subjects. The VCF(C)-EsMWS regressions were similar for both groups, but revealed a minutely higher baseline contractility in the Arg/Arg group (p < 0.01). The β₁-AR Ser49Gly polymorphism had no effect on any of the measured parameters.
CONCLUSIONS: Although the Arg389Gly-β₁-AR polymorphism has only minor relevance for LV contractility it may impact left ventricular size and afterload. The Ser49Gly-β₁-AR polymorphism has no relevant effect on LV geometry or function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20821015     DOI: 10.1007/s00392-010-0221-z

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  34 in total

1.  The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects.

Authors:  K M O'Shaughnessy; B Fu; C Dickerson; D Thurston; M J Brown
Journal:  Clin Sci (Lond)       Date:  2000-09       Impact factor: 6.124

2.  Arg389Gly beta 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo.

Authors:  H G Xie; V Dishy; G Sofowora; R B Kim; R Landau; R M Smiley; H H Zhou; A J Wood; P Harris; C M Stein
Journal:  Pharmacogenetics       Date:  2001-04

Review 3.  Beta-adrenoceptor polymorphisms.

Authors:  K Leineweber; R Büscher; H Bruck; O-E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-28       Impact factor: 3.000

4.  Polymorphism in the beta(1)-adrenergic receptor gene and hypertension.

Authors:  K Bengtsson; O Melander; M Orho-Melander; U Lindblad; J Ranstam; L Råstam; L Groop
Journal:  Circulation       Date:  2001-07-10       Impact factor: 29.690

5.  The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity.

Authors:  Heike Bruck; Kirsten Leineweber; Thomas Temme; Melanie Weber; Gerd Heusch; Thomas Philipp; Otto-Erich Brodde
Journal:  J Am Coll Cardiol       Date:  2005-11-04       Impact factor: 24.094

6.  A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor.

Authors:  D A Mason; J D Moore; S A Green; S B Liggett
Journal:  J Biol Chem       Date:  1999-04-30       Impact factor: 5.157

7.  Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking.

Authors:  Deborah A Rathz; Kari M Brown; Lisa A Kramer; Stephen B Liggett
Journal:  J Cardiovasc Pharmacol       Date:  2002-02       Impact factor: 3.105

8.  Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol.

Authors:  Lu Chen; Deborah Meyers; George Javorsky; Darryl Burstow; Pakorn Lolekha; Margaret Lucas; Annalese B T Semmler; Santiyagu M Savarimuthu; Kwun M Fong; Ian A Yang; John Atherton; Andrew J Galbraith; William A Parsonage; Peter Molenaar
Journal:  Pharmacogenet Genomics       Date:  2007-11       Impact factor: 2.089

9.  Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared to Arg389-beta1-adrenoceptors.

Authors:  S S Joseph; J A Lynham; A A Grace; W H Colledge; A J Kaumann
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

10.  Beta-adrenergic receptor gene polymorphisms and hemodynamic response to dobutamine during dobutamine stress echocardiography.

Authors:  C L Aquilante; H N Yarandi; L H Cavallari; T E Andrisin; S G Terra; J F Lewis; K K Hamilton; J A Johnson
Journal:  Pharmacogenomics J       Date:  2008-02-05       Impact factor: 3.550

View more
  5 in total

1.  Septic cardiomyopathy: hemodynamic quantification, occurrence, and prognostic implications.

Authors:  Karl Werdan; Anja Oelke; Stefan Hettwer; Sebastian Nuding; Sebastian Bubel; Robert Hoke; Martin Russ; Christine Lautenschläger; Ursula Mueller-Werdan; Henning Ebelt
Journal:  Clin Res Cardiol       Date:  2011-02-11       Impact factor: 5.460

2.  The Arg389Gly β1-adrenoceptor gene polymorphism influences the acute effects of β-adrenoceptor blockade on contractility in the human heart.

Authors:  Michael Huntgeburth; Karl La Rosée; Henrik ten Freyhaus; Michael Böhm; Petra Schnabel; Martin Hellmich; Stephan Rosenkranz
Journal:  Clin Res Cardiol       Date:  2011-02-11       Impact factor: 5.460

3.  Beta-adrenergic receptors gene polymorphisms are associated with cardiac contractility and blood pressure variability.

Authors:  L Matuskova; B Czippelova; Z Turianikova; D Svec; Z Kolkova; Z Lasabova; M Javorka
Journal:  Physiol Res       Date:  2021-12-31       Impact factor: 1.881

Review 4.  Adrenergic receptors gene polymorphisms and autonomic nervous control of heart and vascular tone.

Authors:  L Matušková; M Javorka
Journal:  Physiol Res       Date:  2021-12-30       Impact factor: 2.139

Review 5.  Ivabradine: potential clinical applications in critically ill patients.

Authors:  Vincenzo De Santis; Domenico Vitale; Anna Santoro; Aurora Magliocca; Andrea Giuseppe Porto; Cecilia Nencini; Luigi Tritapepe
Journal:  Clin Res Cardiol       Date:  2012-10-14       Impact factor: 5.460

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.